AU-011 is a first-in-class VDC therapy in which the virus-like component of the agent selectively binds unique heparin sulphate proteoglycans (HSPGs), which are modified and overexpressed on the tumor cell surface of malignant cells in the choroid so that a potent cytotoxic drug that is activated with infrared light can be delivered.